Related references
Note: Only part of the references are listed.Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers
Colles Price et al.
CANCER RESEARCH (2019)
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Kristen E. Mengwasser et al.
MOLECULAR CELL (2019)
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Edmond M. Chan et al.
NATURE (2019)
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
Fiona M. Behan et al.
NATURE (2019)
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Simone Lieb et al.
ELIFE (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability
Lorn Kategaya et al.
ISCIENCE (2019)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Xue Gao et al.
NATURE (2018)
Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens
Fadi J. Najm et al.
NATURE BIOTECHNOLOGY (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Silvana Konermann et al.
CELL (2018)
Mapping the Genetic Landscape of Human Cells
Max A. Horlbeck et al.
CELL (2018)
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A. Hoadley et al.
CELL (2018)
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Max D. Wellenstein et al.
IMMUNITY (2018)
History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology
Yoshizumi Ishino et al.
JOURNAL OF BACTERIOLOGY (2018)
Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein
Winston X. Yan et al.
MOLECULAR CELL (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Field-deployable viral diagnostics using CRISPR-Cas13
Cameron Myhrvold et al.
SCIENCE (2018)
Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6
Jonathan S. Gootenberg et al.
SCIENCE (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Complex pattern of immune evasion in MSI colorectal cancer
Mine Ozcan et al.
ONCOIMMUNOLOGY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
[Anonymous]
NATURE REVIEWS DRUG DISCOVERY (2018)
Tumor immune evasion arises through loss of TNF sensitivity
Conor J. Kearney et al.
SCIENCE IMMUNOLOGY (2018)
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth
Shane P. Duggan et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2018)
CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine
Martin Kampmann
ACS CHEMICAL BIOLOGY (2018)
Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array
Bernd Zetsche et al.
NATURE BIOTECHNOLOGY (2017)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
A comprehensive map of molecular drug targets
Rita Santos et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Multiplexed Engineering and Analysis of Combinatorial Enhancer Activity in Single Cells
Shiqi Xie et al.
MOLECULAR CELL (2017)
RNA targeting with CRISPR-Cas13
Omar O. Abudayyeh et al.
NATURE (2017)
Programmable base editing of A.T to G.C in genomic DNA without DNA cleavage
Nicole M. Gaudelli et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
Kyuho Han et al.
NATURE BIOTECHNOLOGY (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
Genetic interaction mapping in mammalian cells using CRISPR interference
Dan Du et al.
NATURE METHODS (2017)
Pooled CRISPR screening with single-cell transcriptome readout
Paul Datlinger et al.
NATURE METHODS (2017)
Diversity and evolution of class 2 CRISPR-Cas systems
Sergey Shmakov et al.
NATURE REVIEWS MICROBIOLOGY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
RNA editing with CRISPR-Cas13
David B. T. Cox et al.
SCIENCE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map
Ian Smith et al.
PLOS BIOLOGY (2017)
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
Julian P. Layer et al.
ONCOIMMUNOLOGY (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Jean-Pierre Delord et al.
CLINICAL CANCER RESEARCH (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
Diversity, classification and evolution of CRISPR-Cas systems
Eugene V. Koonin et al.
CURRENT OPINION IN MICROBIOLOGY (2017)
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Jessica C. Hassel et al.
CANCER TREATMENT REVIEWS (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
Diego Adhemar Jaitin et al.
CELL (2016)
Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens
Atray Dixit et al.
CELL (2016)
A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response
Britt Adamson et al.
CELL (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA
Ines Fonfara et al.
NATURE (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Alexis C. Komor et al.
NATURE (2016)
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
Bastiaan Evers et al.
NATURE BIOTECHNOLOGY (2016)
Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
David W. Morgens et al.
NATURE BIOTECHNOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM
Alan S. L. Wong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis et al.
SCIENCE (2016)
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Gregory V. Kryukov et al.
SCIENCE (2016)
Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Keiji Nishida et al.
SCIENCE (2016)
C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Omar O. Abudayyeh et al.
SCIENCE (2016)
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
Andrew J. Aguirre et al.
CANCER DISCOVERY (2016)
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
Katya Marjon et al.
CELL REPORTS (2016)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Richard S. Finn et al.
BREAST CANCER RESEARCH (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Bernd Zetsche et al.
CELL (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi et al.
NATURE (2015)
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Pedro A. Mateos-Gomez et al.
NATURE (2015)
Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ
Tatiana Kent et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ
Tatiana Kent et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
Anirudh Prahallad et al.
CELL REPORTS (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
Maria Giuseppina Baratta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Luke A. Gilbert et al.
CELL (2014)
Polymerase theta-mediated end joining of replication-associated DNA breaks in C.elegans
Sophie F. Roerink et al.
GENOME RESEARCH (2014)
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Boris G. Wilson et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Gregory R. Hoffman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Genetic Screens in Human Cells Using the CRISPR-Cas9 System
Tim Wang et al.
SCIENCE (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies
Glenn S. Cowley et al.
SCIENTIFIC DATA (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Takahiro Oike et al.
CANCER RESEARCH (2013)
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Lei S. Qi et al.
CELL (2013)
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Luke A. Gilbert et al.
CELL (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
DGIdb: mining the druggable genome
Malachi Griffith et al.
NATURE METHODS (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
Tara R. Rheault et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
Nir Hacohen et al.
CANCER IMMUNOLOGY RESEARCH (2013)
LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer
Fanny Dupuy et al.
CANCER & METABOLISM (2013)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Passenger deletions generate therapeutic vulnerabilities in cancer
Florian L. Muller et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
siRNA off-target effects in genome-wide screens identify signaling pathway members
Eugen Buehler et al.
SCIENTIFIC REPORTS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
International network of cancer genome projects
Thomas J. Hudson et al.
NATURE (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Dual Roles for DNA Polymerase Theta in Alternative End-Joining Repair of Double-Strand Breaks in Drosophila
Sze Ham Chan et al.
PLOS GENETICS (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
J. Mullenders et al.
ONCOGENE (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway
William G. Kaelin et al.
MOLECULAR CELL (2008)
The art and design of genetic screens: RNA interference
Michael Boutros et al.
NATURE REVIEWS GENETICS (2008)
Low-fidelity DNA synthesis by human DNA polymerase theta
Mercedes E. Arana et al.
NUCLEIC ACIDS RESEARCH (2008)
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
Archana Bommi-Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia:: historical comparison between two phase 3 trials
Lydia Roy et al.
BLOOD (2006)
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
A Birmingham et al.
NATURE METHODS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
The art and design of genetic screens: Mammalian culture cells
S Grimm
NATURE REVIEWS GENETICS (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Noise amidst the silence: off-target effects of siRNAs?
AL Jackson et al.
TRENDS IN GENETICS (2004)
The druggable genome
AL Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
Share Paper
